The latest EATRIS journal article – titled ‘Developing harmonized immune platforms: a must-have for realizing personalized therapies in solid tumors’ – has been published in ‘Cell & Gene Therapy Insights’.
The paper introduces the need and strength of the new EATRIS Platform: the Vaccine, inflammation and immune monitoring Platform. The manuscript focuses on essential harmonized immune platforms for realizing personalised therapies, specifically in solid tumours and its importance to the research field. Through the development of harmonized immune platforms made up of inter-disciplinary teams for personalized therapies in solid tumours, the authors suggest that this can: “provide the optimum innovation strategy and ensure reduction in the present failure rates. Done right, this can further advance the development of must-have therapies to the clinic for the right patients at the right time and at the right dose.”
The paper was co-authored by the EATRIS Chairs and received valuable input from the EATRIS science team.
Reference: Morrow, D., Langermans, J., Ussi, A., Andreu, A.L., & Gabriele, L. (2020). Developing harmonized immune platforms: a must-have for realizing personalized therapies in solid tumors. Cell & Gene Therapy Insights. 6(9), 1231–1235. DOI: 10.18609/cgti.2020.139